Flt3 ligand and conjugation to IL-1β peptide as adjuvants for a type 1, T-cell response to an HIV p17 gag vaccine

Vaccine

Volumn 20, Issue 17-18, 2002, Pages 2358-2368

  Pisarev, Vladimir M ^a   Parajuli, Prahlad ^a   Mosley, R Lee ^a   Chavez, Jennifer ^a   Zimmerman, Daniel ^b   Winship, Douglas ^b   Talmadge, James E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b CEL SCI Corporation   (United States)

Author keywords

Flt3 ligand; Gag; IL 1 fragment; Peptide conjugates; Vaccine

Indexed keywords

HISTIDINYLGLYCYLPROLINE 30; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 1BETA; KEYHOLE LIMPET HEMOCYANIN; LIGAND; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; BIOASSAY; CONJUGATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; CELL DIVISION; DENDRITIC CELLS; FEMALE; HEMOCYANIN; HIV ANTIGENS; HYPERSENSITIVITY, DELAYED; INTERFERON TYPE II; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-4; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDES; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TH2 CELLS; VACCINES, CONJUGATE;

EID: 0037157270     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00096-8     Document Type: Article

References (57)

1. Vaccine-induced cytotoxic T lymphocytes protect against retroviral challenge
2. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
3. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy
4. Levels of human immunodeficiency virus type 1-specific cytotoxic T- lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy
5. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
6. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment
7. Therapeutic vaccines in HIV-1 infection
8. HIV-1 variation diminishes CD4 T lymphocyte recognition
9. Coexisting members of HIV-1 p17 gene quasispecies represent proteins with distinct antigenicity and immunogenicity
10. Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection
11. Characterization of mother-infant HIV type 1 p17 gag sequences associated with perinatal transmission
12. HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals
13. Immune response and epitope mapping of a candidate HIV-1 p17 vaccine HGP30
14. HIV-1-specific cytotoxic T lymphocyte response in healthy, long-term nonprogressing seropositive persons
15. Random expression of human immunodeficiency virus-1 (HIV-1) p17 (epitopes) on the surface of the HIV-1-infected cell
16. Cross-clade p17 peptide recognition by antisera to HGP-30, a 30-amino acid synthetic peptide antigen from HIV type 1 p17
17. Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine - HGP-30-KLH
18. Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice
19. The search for a potent DNA vaccine against AIDS: The enhancement of immunogenicity by chemical and genetic adjuvants
20. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV
21. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose- dependent manner
22. Cloning of the human homologue of the murine flt3 ligand: A growth factor for early hematopoietic progenitor cells
23. Prevention of peripheral tolerance by a dendritic cell growth factor: Flt3 ligand as an adjuvant
24. Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine
25. Immunization with wild-type p53 gene sequences co-administered with Flt3 ligand, induces an antigen-specific type 1 T-cell response
26. A new approach to T-cell activation: Natural and synthetic conjugates capable of activating T cells
27. Immunization with peptide heteroconjugates primes a T helper cell type 1-associated antibody (IgG2a) response that recognizes the native epitope on the 38-kDa protein of Mycobacterium tuberculosis
28. Bioactive fragment of human interleukin-1β (163-171) modulates the immune response to synthetic peptides of RESA of Plasmodium falciparum
29. Enhanced immunogenicity of a sequence derived from hepatitis B virus surface antigen in a composite peptide that includes the immunostimulatory region from human interleukin 1
30. Interleukin 1 and its synthetic peptides as adjuvants for poorly immunogenic vaccines
31. Interleukin-1 derived synthetic peptide as an added co-adjuvant in vaccine formulations
32. Cytokines as vaccine adjuvants: Interleukin 1 and its synthetic peptide 163-171
33. A nine-amino acid peptide from IL-1β augments antitumor immune responses induced by protein and DNA vaccines
34. DNA vaccination with cytokine fusion constructs biases the immune response to ovalbumin
35. In vivo immunostimulating activity of the 163-171 peptide of human IL-1β
36. Bioactive fragment of human IL-1β (163-171) modulates the immune response to synthetic peptides of HIV
37. Peptide binding to MHC class I molecules: Implications for antigenic peptide prediction
38. Comparison of the hematopoietic activity of flt-3 ligand and granulocyte-macrophage colony-stimulating factor acting alone or in combination
39. Ligand for Flt3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs
40. + bone marrow progenitor cells in vitro
41. -) human hematopoietic cells: Novel responses to Flt3 ligand and thrombopoietin
42. Biologic effects and potential clinical applications of Flt3 ligand
43. Flk2/Flt3 ligand is a potent cofactor for the growth of primitive B cell progenitors
44. Differential effects of Flk-2/Flt-3 ligand and stem cell factor on murine thymic progenitor cells
45. Polyomavirus-infected dendritic cells induce antiviral CD8(+) T lymphocytes
46. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified
47. Dramatic numerical increase of functionally mature dendritic cells in Flt3 ligand-treated mice
48. In vivo administration of Flt3 ligand markedly stimulates generation of dendritic cell progenitors from mouse liver
49. Flt3 ligand and granulocyte-macrophage colony-stimulation factor preferentially expand and stimulate different dendritic cell and T-cell subsets
50. Dendritic cells and the control of immunity
51. Antigen processing for amateurs and professionals
52. Transport of peptide-MHC class II complexes in developing dendritic cells
53. Functional skewing of bone marrow-derived dendritic cells by Th1- or Th2-inducing cytokines
54. T cells and dendritic cells get intimate
55. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo
56. Interleukin-1 and interleukin-1 fragments as vaccine adjuvants
57. Modulating dendritic cells to optimize mucosal immunization protocols